| Bioactivity | Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1]. |
| Invitro | Bivatuzumab (10 μg/mL) stains CD44v6 in STS cells[1]. |
| Name | Bivatuzumab |
| CAS | 214559-60-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167. |